Approval · Notice of Compliance 34516 · 2024
SHINGRIX: Notice of Compliance 34516
Issued December 6, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34516
- Date
- December 6, 2024
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Labelling updates
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SHINGRIX | Not yet assigned | — |
Medicinal ingredients
- VARICELLA-ZOSTER VIRUS GLYCOPROTEIN E (GE) 50 MCG per 0.5ML